Kede Numerical Control Stalls Amid Persistent Valuation Concerns
Kede Numerical Control (688305.SS) closed the trading session on Thursday, 22 November 2026, at a flat 0 % relative to the previous close, trading at CNY 45.65 on major exchanges. The stock’s market cap hovers at CNY 6 billion with a circulating supply of 133.1 million shares. In the last 24 hours, the company saw a turnover of CNY 55.7 million, a figure that is negligible against its valuation and trading volume.
A Troubling Trend
Since the end of last month, Kede’s share price has plunged 22.08 %, underscoring a lack of confidence among investors. The simple moving average over the past 200 days sits at CNY 59.9, a level that is over CNY 14 above today’s price—an alarming gap that suggests the stock is trading well below its recent historical average. Even when measured against its 52‑week high of CNY 80.69 (recorded on 7 February 2026), the current price is over 30 % lower, while the 52‑week low of CNY 43.8 (on 19 October 2026) is only marginally below today’s level.
Peer Comparison Reveals a Wider Issue
The stagnation is not isolated to Kede. Several peers in the precision manufacturing and technology sectors also show flat or negative performance:
| Stock | 24‑Hour Change | Current Price | Market Cap | P/E Ratio |
|---|---|---|---|---|
| Shanghai Yanpu Precision T (605128.SS) | 0 % | CNY 22.39 | CNY 7.2 bn | 45.19 |
| Beijing Topnew Info&Tech C (300895.SZ) | 0 % | CNY 45.31 | CNY 7.2 bn | – |
| Catarc Automotive Proving (301215.SZ) | 0 % | CNY 5.30 | CNY 7.2 bn | 28.59 |
| Nanjing Leads Biolabs L-h (9887.HK) | –7.03 % | HKD 36.68 | HKD 8.4 bn | – |
| Guilin Sanjin Pharmaceuticals (002275.SZ) | 0 % | CNY 12.07 | CNY 7.2 bn | 17.58 |
These figures paint a picture of a market segment that is either overvalued or failing to deliver on growth expectations. Kede’s P/E dynamics are not disclosed, yet its price trajectory suggests a disconnect between intrinsic value and market sentiment.
The Bottom Line
Kede Numerical Control’s flat performance, coupled with a steep decline since the previous month, raises serious questions about its growth prospects and valuation rationality. The company’s price has already eroded a significant portion of its recent gains, and the gap between its current level and the 200‑day average signals potential upside pressure that investors are reluctant to acknowledge.
Unless Kede delivers a compelling turnaround—through product innovation, market expansion, or cost discipline—its shareholders are likely to witness further erosion in value. The market’s tepid response to the stock’s latest trading activity should serve as a stark warning: expectations outstripped by reality.
